Menu
Search
|

Menu

Close
X

Trevena Inc TRVN.OQ (NASDAQ Stock Exchange Global Select Market)

1.41 USD
-0.01 (-0.70%)
As of Jul 20
chart
Previous Close 1.42
Open 1.44
Volume 127,684
3m Avg Volume 216,636
Today’s High 1.44
Today’s Low 1.39
52 Week High 3.00
52 Week Low 1.35
Shares Outstanding (mil) 72.58
Market Capitalization (mil) 103.07
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
4
FY15
6
EPS (USD)
FY18
-0.140
FY17
-1.216
FY16
-1.958
FY15
-1.156
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
--
8.11
Price to Book (MRQ)
vs sector
2.62
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
69.07
17.18
LT Debt to Equity (MRQ)
vs sector
34.76
13.08
Return on Investment (TTM)
vs sector
-82.82
13.18
Return on Equity (TTM)
vs sector
-116.14
15.09

EXECUTIVE LEADERSHIP

Leon Moulder
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Maxine Gowen
President, Chief Executive Officer, Director, Since
Salary: $513,917.00
Bonus: --
John Hamill
Interim Principal Financial Officer and Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
Carrie Bourdow
Chief Operating Officer, Executive Vice President, Since 2018
Salary: --
Bonus: --
John Limongelli
Chief Administrative Officer, Senior Vice President, General Counsel, Secretary, Since 2016
Salary: $330,333.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

955 Chesterbrook Blvd Ste 200
CHESTERBROOK   PA   19087-5625

Phone: +1610.3548840

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

SPONSORED STORIES